Mirae Asset Global Investments Co. Ltd. Has $190.84 Million Holdings in AbbVie Inc. $ABBV

Mirae Asset Global Investments Co. Ltd. grew its position in AbbVie Inc. (NYSE:ABBV) by 3.2% during the third quarter, HoldingsChannel.com reports. The firm owned 824,201 shares of the company’s stock after buying an additional 25,942 shares during the quarter. AbbVie accounts for approximately 0.6% of Mirae Asset Global Investments Co. Ltd.’s investment portfolio, making the stock its 22nd biggest holding. Mirae Asset Global Investments Co. Ltd.’s holdings in AbbVie were worth $190,836,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Conning Inc. raised its stake in AbbVie by 7.1% in the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares in the last quarter. Diversified Trust Co increased its holdings in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after purchasing an additional 10,891 shares during the period. Dohj LLC raised its position in shares of AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after buying an additional 1,335 shares in the last quarter. Permanent Capital Management LP bought a new stake in shares of AbbVie in the third quarter valued at approximately $720,000. Finally, Railway Pension Investments Ltd boosted its stake in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after buying an additional 211,800 shares during the period. Institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analyst endorsement on CNBC: Jason Snipe recommended staying long on AbbVie on CNBC’s “Halftime Report Final Trades,” supporting near-term buyer interest. Article Title
• Positive Sentiment: Big licensing deals: AbbVie and Novartis announced billion-dollar licensing agreements for oncology and Alzheimer’s treatments, which could accelerate development and revenue optionality if milestones are met. Article Title
• Positive Sentiment: Delivery technology update: AbbVie completed a Phase 1 study of an on‑body injector for risankizumab, a potential commercial convenience boost for a key immunology drug. Article Title
• Positive Sentiment: Bullish analyst move: Berenberg raised its price target to $275 (Buy), highlighting momentum in Skyrizi and Rinvoq — supportive for longer-term sentiment. Article Title
• Positive Sentiment: Insider/institutional flow: Belpointe Asset Management increased its stake, a small sign of buying interest from an active manager. Article Title
• Neutral Sentiment: Allergan Aesthetics data: New clinical and patient-satisfaction data on facial injectables (including TrenibotE) were presented at IMCAS — positive for the aesthetics unit but likely a gradual revenue tailwind. Article Title
• Neutral Sentiment: Options and attention: Commentary suggests unusual options activity and investor interest — may presage volatility but not a directional signal by itself. Article Title
• Neutral Sentiment: Corporate philanthropy/CSR: AbbVie Foundation opened applications for a health equity accelerator — positive brand impact but limited near-term stock effect. Article Title
• Neutral Sentiment: Earnings calendar: AbbVie is expected to report quarterly results this week — a potential catalyst for short-term price moves. Article Title
• Negative Sentiment: Medicare price-negotiation listing: CMS named AbbVie drugs for the next round of Medicare Drug Price Negotiations — a material policy risk that could pressure pricing and longer-term revenue for affected products. Article Title
• Negative Sentiment: Competitive threat: Corcept reported robust Phase III ovarian cancer data for a rival candidate, which could challenge AbbVie (and Merck) in that oncology niche if it advances to approval. Article Title
• Negative Sentiment: Price-target trim: Citi lowered its AbbVie price target slightly to $230 and set a Neutral rating — a modest negative signal for sentiment among some institutional analysts. Article Title

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ABBV shares. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research report on Tuesday, November 4th. BMO Capital Markets restated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. Citigroup lowered their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Guggenheim raised their price objective on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $247.84.

AbbVie Stock Performance

AbbVie stock opened at $221.66 on Wednesday. The firm has a 50 day moving average price of $225.14 and a two-hundred day moving average price of $218.00. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm has a market cap of $391.75 billion, a price-to-earnings ratio of 167.44, a PEG ratio of 0.91 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.